CXCL12 and breast cancer: For instance, when human breast cancer cells with constitutive NF-κB activity were treated with NF-κB inhibitors, (overexpression of IκBα or parthenolide treatment), the expression of CXCR4 transcripts was notably reduced, followed by a loss of SDF-1α-mediated migration [86].